PGS Publication: PGP000284

Publication Information (EuropePMC)
Title Are polygenic risk scores for systolic blood pressure and LDL-cholesterol associated with treatment effectiveness, and clinical outcomes among those on treatment?
PubMed ID 34864974(Europe PMC)
doi 10.1093/eurjpc/zwab192
Publication Date Dec. 2, 2021
Journal Eur J Prev Cardiol
Author(s) Tapela NM, Collister J, Liu X, Clifton L, Stiby A, Murgia F, Hopewell JC, Hunter DJ.
Released in PGS Catalog: Feb. 16, 2022

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

External PGS Evaluated By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
Scoring File (FTP Link)
PGS002257
(GRS901_SBP)
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Systolic blood pressure systolic blood pressure 884
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002257/ScoringFiles/PGS002257.txt.gz
PGS000115
(LDL-C_20)
PGP000053 |
Trinder M et al. JAMA Cardiol (2020)
LDL cholesterol low density lipoprotein cholesterol measurement 223
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000115/ScoringFiles/PGS000115.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM012859 PGS000115
(LDL-C_20)
PSS009580|
European Ancestry|
33,787 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Uncontrolled hypercholesterolaemia Odds Ratio (OR, top vs. bottom quintile): 2.78 [2.58, 3.0] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), and the first four principal components of genetic ancestry, genotyping array and systolic blood pressure at baseline 218 SNPs remained after QC
PPM012860 PGS000115
(LDL-C_20)
PSS009577|
European Ancestry|
33,787 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident major adverse cardiovascular events in statin treatment Hazard Ratio (HR, top vs. bottom quintile): 1.03 [0.92, 1.14] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), and the first four principal components of genetic ancestry, genotyping array and systolic blood pressure at baseline 218 SNPs remained after QC
PPM012861 PGS000115
(LDL-C_20)
PSS009578|
European Ancestry|
33,787 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident myocardial infarction in statin treatment Hazard Ratio (HR, top vs. bottom quintile): 1.08 [0.95, 1.23] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), and the first four principal components of genetic ancestry, genotyping array and systolic blood pressure at baseline 218 SNPs remained after QC
PPM012862 PGS000115
(LDL-C_20)
PSS009579|
European Ancestry|
33,787 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident stroke in statin treatment Hazard Ratio (HR, top vs. bottom quintile): 0.93 [0.77, 1.12] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), and the first four principal components of genetic ancestry, genotyping array and systolic blood pressure at baseline 218 SNPs remained after QC
PPM012863 PGS002257
(GRS901_SBP)
PSS009584|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Uncontrolled hypertension Odds Ratio (OR, top vs. bottom quintile): 1.7 [1.6, 1.8] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM012864 PGS002257
(GRS901_SBP)
PSS009581|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident major adverse cardiovascular events in hypertension treatment Hazard Ratio (HR, top vs. bottom quintile): 1.13 [1.04, 1.23] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM012865 PGS002257
(GRS901_SBP)
PSS009582|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident myocardial infarction in hypertension treatment Hazard Ratio (HR, top vs. bottom quintile): 1.08 [0.97, 1.2] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM012866 PGS002257
(GRS901_SBP)
PSS009583|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident stroke in hypertension treatment Hazard Ratio (HR, top vs. bottom quintile): 1.22 [1.06, 1.41] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS009577 Self-reported statin-use. Uncontrolled hypercholesterolaemia was defined as having baseline LDL-cholesterol >_3 mmol/L, among individuals in the treated hypercholesterolaemia sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.4 years
[
  • 3,565 cases
  • , 30,222 controls
]
,
58.5 % Male samples
Mean = 61.7 years European
(white British)
UKB
PSS009578 Self-reported statin-use. Uncontrolled hypercholesterolaemia was defined as having baseline LDL-cholesterol >_3 mmol/L, among individuals in the treated hypercholesterolaemia sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.4 years
[
  • 2,358 cases
  • , 31,429 controls
]
,
58.5 % Male samples
Mean = 61.7 years European
(white British)
UKB
PSS009579 Self-reported statin-use. Uncontrolled hypercholesterolaemia was defined as having baseline LDL-cholesterol >_3 mmol/L, among individuals in the treated hypercholesterolaemia sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.4 years
[
  • 1,207 cases
  • , 32,580 controls
]
,
58.5 % Male samples
Mean = 61.7 years European
(white British)
UKB
PSS009580 Self-reported statin-use. Uncontrolled hypercholesterolaemia was defined as having baseline LDL-cholesterol >_3 mmol/L, among individuals in the treated hypercholesterolaemia sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.4 years
[
  • 11,767 cases
  • , 22,020 controls
]
,
58.5 % Male samples
Mean = 61.7 years European
(white British)
UKB
PSS009581 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 5,596 cases
  • , 49,843 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS009582 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 3,586 cases
  • , 51,853 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS009583 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 2,010 cases
  • , 53,429 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS009584 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 36,114 cases
  • , 19,325 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB